Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Chronic kidney disease of unknown etiology (CKDu) is an emerging public health challenge in tropical agrarian regions, particularly in South Asia. Our centre had previously reported an endemic belt of CKDu from central India. However the rate of kidney disease progression in these patients is not known. This study aimed to characterize the clinical profile and renal progression, of CKDu in a hospital-based cohort from India
We retrospectively reviewed the case records of a total of 345 patients of CKDu followed up at the Department of Nephrology at AIIMS Raipur since 2022. CKDu was diagnosed as per the case definition published by the Indian Society of Nephrology. Kidney function trajectory was assessed using serial eGFR measurements, with annualized decline calculated using linear regression. Progression was categorized as rapid (slope ≤ –5 mL/min/year or ≥40% decline), slow (–5 to –1 mL/min/year), or stable (≥ –1 mL/min/year).
A total of 345 patients with CKDu were enrolled in the study. The median age was 57(47-64) years with 67% males(Table 1). A total of 185 CKDu patients had at least two serial eGFR measurements recorded six months apart and were included in the progression analysis.
The median baseline eGFR was 23.3 mL/min/1.73 m² (IQR 14.3–33.9). Over a median follow-up of approximately 21 months (IQR 19.8–21.8), 66 of 184 patients (35.9%) progressed to eGFR <15 mL/min/1.73 m². A ≥20% decline in eGFR was observed in 61 of 184 patients (33.2%), while 28 patients (15.2%) experienced a ≥40% decline. Doubling of serum creatinine occurred in 13 of 184 patients (7.1%).
Among the 70 patients with analysable follow-up duration (≥12 months), the mean annual eGFR decline was −0.7 ± 2.3 mL/min/1.73 m²/year, with progression phenotypes stratified as rapid in 12 patients (17.1%), slow in 4 patients (5.7%), and stable kidney function in 54 patients (77.1%), Mortality reported was 11% (n=38) in the study.
The study describes slow average eGFR decline in patients with CKDu presenting to our centre. Prospective studies are needed to confirm our findings and delineate the risk factors associated with faster progression.
